Showing 1 - 9 results of 9 for search 'Kang-Shuai Li', query time: 0.03s Refine Results
  1. 1
    Case report: Obstructive jaundice caused by biliary cystadenoma

    Case report: Obstructive jaundice caused by biliary cystadenoma by Yun-cheng Li, An-da Shi, Kang-shuai Li

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects

    Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects by Xiao-Dong Zhu, Kang-Shuai Li, Hui-Chuan Sun

    Published 2020-09-01
    Get full text
    Article
  3. 3
    Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis

    Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis by Kang-Shuai Li, Sen Guo, Yu-Xin Chen, Zong-Li Zhang

    Published 2022-12-01
    Get full text
    Article
  4. 4
    Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma

    Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma by Kang-shuai Li, Yi Liu, Tie-zhong Zhang, Yun-fei Xu, Zong-li Zhang

    Published 2024-11-01
    Get full text
    Article
  5. 5
    Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC

    Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC by Li-xin Du, Guo-li Sheng, An-da Shi, Kang-shuai Li, Zeng-li Liu, Yong-chang Tang, Yi Liu, Zong-li Zhang

    Published 2024-08-01
    Get full text
    Article
  6. 6
    Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

    Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model by Xue-Feng Liu, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Bin Xu, Kang-Shuai Li, Nan Xiao, Ming Lei, Hui-Chuan Sun, Zhao-You Tang

    Published 2022-04-01
    Get full text
    Article
  7. 7
    Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers

    Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers by Yun-cheng Li, Kang-shuai Li, Zeng-li Liu, Yong-chang Tang, Xiao-Qiang Hu, Xing-yong Li, An-da Shi, Li-ming Zhao, Li-Zhuang Shu, Shuo Lian, Zhang-di Yan, Shao-hui Huang, Guo-li Sheng, Yan Song, Yun-jia Liu, Fan Huan, Ming-hui Zhang, Zong-li Zhang

    Published 2022-10-01
    Get full text
    Article
  8. 8
    Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

    Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a by Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin, Hui-Chan Sun, Ti Zhang, Zhao-You Tang

    Published 2018-04-01
    Get full text
    Article
  9. 9
    miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

    miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a by Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Ke-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin, Hui-Chuan Sun, Ti Zhang, Zhao-You Tang

    Published 2018-01-01
    Get full text
    Article

Search Tools: